Edgewise Networks will significantly improve the security of east-west communication by verifying the identity of application software, services and processes, Zscaler said. Zscaler has purchased ...

January 13, 2025--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

Edgewise Therapeutics stock skyrocketed to a three-year high on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. Please watch the video at Investors.com ...

Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. The stock rose 5.4% to $29.11 ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the ...

Additionally, Edgewise is set to report significant data from its Phase 2 studies in Duchenne muscular dystrophy in the first half of 2025, which will further guide their Phase 3 planning.

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease Edgewise Therapeutics reports promising Phase 2 results for sevasemten ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...